Search hospitals > Ontario > TORONTO
University Health Network, Princess Margaret Hospital
Claim this profileTORONTO, Ontario M5G 2M9
Global Leader in Skin Cancer
Global Leader in Relapse
Conducts research for Breast Cancer
Conducts research for Prostate Cancer
Conducts research for Cancer
300 reported clinical trials
31 medical researchers
Summary
University Health Network, Princess Margaret Hospital is a medical facility located in TORONTO, Ontario. This center is recognized for care of Skin Cancer, Relapse, Breast Cancer, Prostate Cancer, Cancer and other specialties. University Health Network, Princess Margaret Hospital is involved with conducting 300 clinical trials across 438 conditions. There are 31 research doctors associated with this hospital, such as Amit Oza, MD, Lillian Siu, MD, Philippe Bedard, and Marcus Butler.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage I
2Relapse
Global LeaderStage IV
Stage III
BRCA1 positive
Top PIs
Amit Oza, MDPrincess Margaret Cancer Centre5 years of reported clinical research
Expert in Ovarian Cancer
Studies Fallopian Tube Cancer
30 reported clinical trials
50 drugs studied
Lillian Siu, MDPrincess Margaret Cancer Centre6 years of reported clinical research
Studies Solid Tumors
Studies Breast Cancer
18 reported clinical trials
42 drugs studied
Philippe BedardPrincess Margaret Cancer Centre3 years of reported clinical research
Studies Breast Cancer
Studies Uterine Tumors
16 reported clinical trials
27 drugs studied
Marcus ButlerPrincess Margaret Cancer Centre8 years of reported clinical research
Studies Skin Cancer
Studies Melanoma
15 reported clinical trials
27 drugs studied
Clinical Trials running at University Health Network, Princess Margaret Hospital
Skin Cancer
Prostate Cancer
Cancer
Urothelial Carcinoma
Uterine Tumors
Testicular cancer
Myelodysplastic Syndrome
Bladder Cancer
Pancreatic Cancer
Small Cell Lung Cancer
MRI Monitoring vs. Preventive Brain Radiation
for Small Cell Lung Cancer
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.
Recruiting2 awards Phase 322 criteria
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy
for Brain Metastasis from Lung Cancer
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.
Recruiting2 awards Phase 315 criteria
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University Health Network, Princess Margaret Hospital?
University Health Network, Princess Margaret Hospital is a medical facility located in TORONTO, Ontario. This center is recognized for care of Skin Cancer, Relapse, Breast Cancer, Prostate Cancer, Cancer and other specialties. University Health Network, Princess Margaret Hospital is involved with conducting 300 clinical trials across 438 conditions. There are 31 research doctors associated with this hospital, such as Amit Oza, MD, Lillian Siu, MD, Philippe Bedard, and Marcus Butler.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.